The SCiStar study is an open - label, single - arm trial testing three sequential escalating doses of AST - OPC1 administered at up to 20 million AST - OPC1 cells in 25 subjects with
subacute motor complete (AIS - A or AIS - B) cervical (C - 4 to C - 7) spinal cord injury.